FGF23 and chronic kidney disease: In another study, Gonzalez-Parra et al. (2011) showed that treatment with the phosphate binder lanthanum carbonate in stage 3 CKD patients was associated with a decrease in serum FGF-23 levels and a decrease in the risk of adverse cardiovascular events.